---
title: 'Rationale and design of the multicenter, national, randomized, open labeled
  phase III trial: allogeneic stem cell transplantation as a potential curative treatment
  for patients with relapsed or progressed multiple myeloma (AlloRelapseMM Study)'
date: '2025-01-26'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39865222/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20250127170523&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'BACKGROUND: Even though major improvements have been made in the treatment
  of myeloma, the majority of patients eventually relapse or progress. Patients with
  multiple myeloma who relapse after initial high-dose chemotherapy with autologous
  stem cells have a median progression free survival up to 2-3 years, depending on
  risk factors such as previous remission duration. In recent years, growing evidence
  has suggested that allogeneic stem cell transplantation could be a promising treatment
  ...'
disable_comments: true
---
BACKGROUND: Even though major improvements have been made in the treatment of myeloma, the majority of patients eventually relapse or progress. Patients with multiple myeloma who relapse after initial high-dose chemotherapy with autologous stem cells have a median progression free survival up to 2-3 years, depending on risk factors such as previous remission duration. In recent years, growing evidence has suggested that allogeneic stem cell transplantation could be a promising treatment ...